Toward Translation of Nanotechnology Cancer Interventions (TTNCI; R01 Clinical Trial Not Allowed)
Last verified by NonDilute: 2026-04-29. Official notice and agency instructions control.
Mature your nanoparticle or nano-device cancer therapy from bench to a stage competitive for clinical development, with NIH funding explicitly designed to bridge that gap.
Report stale or inaccurate summary
What this is
This NIH/NCI grant funds basic-to-translational research on nanotechnology cancer interventions, focusing on nanoparticles and nano-devices that combine structural design with therapeutic or diagnostic cargo. Applicants must demonstrate strong pre-clinical evidence that their nanomedicine approach improves cancer treatment effectiveness. The goal is to advance these technologies from the lab to a stage ready for further development via NCI's NExT and other translational pipelines. Clinical trials are explicitly not allowed under this mechanism.
Who can apply
Very broad eligibility including small businesses, nonprofits with or without 501(c)(3) status, for-profit organizations, universities (public and private), government agencies, and tribal organizations. No geographic restriction mentioned. Applicant must conduct advanced pre-clinical research on nanotechnology cancer interventions; clinical trials are not permitted.
Eligible applicant types
- County governments
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- Native American tribal organizations (other than Federally recognized tribal governments)
- City or township governments
- Special district governments
- Native American tribal governments (Federally recognized)
- Small businesses
- State governments
- Independent school districts
- Public and State controlled institutions of higher education
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Public housing authorities/Indian housing authorities
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- For profit organizations other than small businesses
Full description — from the agency
Through this Notice of Funding Opportunity (NOFO), entitled "Toward Translation of Nanotechnology Cancer Interventions" (TTNCI), the National Cancer Institute (NCI) encourages applications for advanced pre-clinical research, supporting translation of nanotechnology-based cancer diagnostics and therapeutics. TTNCI awards are designed to mature experimental nanomedicines relying on nanoparticles and nano-devices which demonstrate strong potential to improve cancer treatment effectiveness due to the combination of nanoparticle/nano-device structural design and/or therapeutic/diagnostic cargo which is delivered. TTNCI awards are expected to enable further development of proposed nanotechnology-based interventions to the stage in which they could continue on a developmental path towards the NCI Experimental Therapeutics (NExT) and other NCI translational programs.
Topics: nanoparticle cancer therapy · nanomedicine development · cancer diagnostics · nano-device therapeutics · translational cancer research · preclinical nanomedicine · NCI funding · cancer intervention
Public-source funding discovery only. This summary is generated from public agency data and may be incomplete or stale. NonDilute is not affiliated with, endorsed by, or acting on behalf of any government agency. Official notices and agency instructions control. NonDilute does not determine eligibility, provide grant-writing advice, or guarantee funding.